458 related articles for article (PubMed ID: 10987229)
1. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
[TBL] [Abstract][Full Text] [Related]
2. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
3. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
Berns EM; van Staveren IL; Look MP; Smid M; Klijn JG; Foekens JA
Br J Cancer; 1998 Apr; 77(7):1130-6. PubMed ID: 9569050
[TBL] [Abstract][Full Text] [Related]
4. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
Foulkes WD; Chappuis PO; Wong N; Brunet JS; Vesprini D; Rozen F; Yuan ZQ; Pollak MN; Kuperstein G; Narod SA; Bégin LR
Ann Oncol; 2000 Mar; 11(3):307-13. PubMed ID: 10811497
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
[TBL] [Abstract][Full Text] [Related]
6. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
[TBL] [Abstract][Full Text] [Related]
7. Breast-cancer stromal cells with TP53 mutations and nodal metastases.
Patocs A; Zhang L; Xu Y; Weber F; Caldes T; Mutter GL; Platzer P; Eng C
N Engl J Med; 2007 Dec; 357(25):2543-51. PubMed ID: 18094375
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group.
Kucera E; Speiser P; Gnant M; Szabo L; Samonigg H; Hausmaninger H; Mittlböck M; Fridrik M; Seifert M; Kubista E; Reiner A; Zeillinger R; Jakesz R
Eur J Cancer; 1999 Mar; 35(3):398-405. PubMed ID: 10448289
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Fernández-Cuesta L; Oakman C; Falagan-Lotsch P; Smoth KS; Quinaux E; Buyse M; Dolci MS; Azambuja ED; Hainaut P; Dell'orto P; Larsimont D; Francis PA; Crown J; Piccart-Gebhart M; Viale G; Leo AD; Olivier M
Breast Cancer Res; 2012 May; 14(3):R70. PubMed ID: 22551440
[TBL] [Abstract][Full Text] [Related]
11. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
Lin CH; Lu YS; Huang CS; Kuo KT; Wang CC; You SL; Lin PH; Chang DY; Kuo WH; Chang KJ; Cheng AL
J Clin Pathol; 2011 Sep; 64(9):781-7. PubMed ID: 21642658
[TBL] [Abstract][Full Text] [Related]
12. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer.
Offersen BV; Alsner J; Ege Olsen K; Riisbro R; Brünner N; Sørensen FB; Sørensen BS; Schlemmer BO; Overgaard J
Acta Oncol; 2008; 47(4):618-32. PubMed ID: 18465330
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
14. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.
Berns EM; Klijn JG; Smid M; van Staveren IL; Look MP; van Putten WL; Foekens JA
Genes Chromosomes Cancer; 1996 Jul; 16(3):170-9. PubMed ID: 8814449
[TBL] [Abstract][Full Text] [Related]
15. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
16. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.
Andersson J; Larsson L; Klaar S; Holmberg L; Nilsson J; Inganäs M; Carlsson G; Ohd J; Rudenstam CM; Gustavsson B; Bergh J
Ann Oncol; 2005 May; 16(5):743-8. PubMed ID: 15802278
[TBL] [Abstract][Full Text] [Related]
17. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
18. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.
Alsner J; Yilmaz M; Guldberg P; Hansen LL; Overgaard J
Clin Cancer Res; 2000 Oct; 6(10):3923-31. PubMed ID: 11051239
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
